聚焦2026年二季度生物制药报告:资金突破100亿美元,创纪录退出(英)-2026。Biopharma VC funding topped $10 billion for only the third time since early 2022. Nearly 20% of Q2 deal value came from Isomorphic’s record $2.1 billion Series B.The segment has had flat growth with few mega-rounds despite validated mechanisms and approved drugs on the market.
聚焦2026年二季度生物制药报告:资金突破100亿美元,创纪录退出(英)-2026。Biopharma VC funding topped $10 billion for only the third time since early 2022. Nearly 20% of Q2 deal value came from Isomorphic’s record $2.1 billion Series B.The segment has had flat growth with few mega-rounds despite validated mechanisms and approved drugs on the market.
聚焦2026年二季度生物制药报告:资金突破100亿美元,创纪录退出(英)-2026。Biopharma VC funding topped $10 billion for only the third time since early 2022. Nearly 20% of Q2 deal value came from Isomorphic’s record $2.1 billion Series B.The segment has had flat growth with few mega-rounds despite validated mechanisms and approved drugs on the market.
本报告由PitchBook发布,发布于 2026 年。
覆盖 2026 年,全文共 16 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
适合行业研究员、战略规划等读者参考。
重点分析了生物制药、2026年二季度生物制药报告等议题。